Squalamine

Drug Profile

Squalamine

Alternative Names: EVIZON; MSI-1256F; OHR 102; Squalamine lactate

Latest Information Update: 29 Dec 2016

Price : $50

At a glance

  • Originator Genaera Corporation
  • Developer Genaera Corporation; Ohr Pharmaceutical
  • Class Antineoplastics; Cholestanols; Eye disorder therapies; Lactates; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Fibroblast growth factor inhibitors; Platelet-derived growth factor inhibitors; Vascular endothelial growth factor C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Wet age-related macular degeneration
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Wet age-related macular degeneration
  • Phase II Diabetic macular oedema; Diabetic retinopathy; Retinal vein occlusion
  • Discontinued Fibrodysplasia ossificans progressiva; Non-small cell lung cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 22 Dec 2016 Updated efficacy data from the phase II IMPACT trial in Wet age-related macular degeneration released by Ohr Pharmaceutical
  • 29 Mar 2016 Phase-III clinical trials in Wet age-related macular degeneration (Combination therapy, Newly diagnosed, Treatment-naive) in USA, Canada (Ophthalmic)
  • 29 Mar 2016 Ohr Pharmaceutical reaches a Special Protocol Assessment agreement with the US FDA for phase III trials in Wet age-related macular degeneration
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top